Industry veteran Catherine Owen Adams expects external innovation will be key to getting the brain-focused drug developer to “the next level.” ...

Positive data on depression treatment based on a drug related to the psychedelic DMT is breathing life into shares of ...

Life Sciences & Beckley Psytech announce positive results from phase 2b study of BPL-003 in patients with treatment-resistant depression: New York Wednesday, July 2, 2025, 10 ...

Cosmo Feilding Mellen – currently Beckley's chief executive, who is slated to serve as chief strategy officer of the merged ...

A psychedelic nasal spray requiring a much shorter period of clinical supervision has shown promise against ...

Atai Life Sciences’ psychedelic drug has successfully reduced the symptoms of depression in a phase 2 study, triggering the next stage of the biotech’s planned merger with mental health company ...

A drug used for Parkinson's disease has been shown to be effective in reducing the symptoms of difficult to treat depression, ...

NRx Pharmaceuticals (NASDAQ: NRXP) , via its wholly owned subsidiary HOPE Therapeutics(TM), Inc., has signed a binding Letter of Intent to acquire a ...

NRx Pharmaceuticals (NASDAQ: NRXP), via its wholly owned subsidiary HOPE Therapeutics (TM), Inc., has signed a binding Letter ...

Though caution is required when the data haven't been published, it could be a landmark in the drug's journey toward FDA ...

Compass Pathways Plc’s shares plummeted after its psychedelic drug to treat a form of depression disappointed investors in a ...

While positive, results from a late-stage clinical trial appear to be raising questions about how useful the company’s ...